Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - ALAPH LN

8 Apr 2025 15:30

RNS Number : 1620E
Syquant Capital
08 April 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

SYQUANT CAPITAL

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

April 7, 2025

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

38,456,482

7.11%

 

 

(2) Derivatives (other than options):

4,988,300

0.92%

 

(3) Options and agreements to purchase/sell:

 

 

 

 

TOTAL:

43,444,782

8.03%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

1p ordinary

 

CFD

 

reducing a long position

 

82,111

 

64.3 GBp

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

April 8, 2025

Contact name:

Laurent Boscherel

Telephone number:

+33 1 42 56 56 27

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETFLFELSTITIIE
Date   Source Headline
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
1st Dec 20177:00 amRNSAcquisition of AmetopT
17th Oct 20179:14 amRNSHardman Research: Kelo-cote international sales
13th Sep 20177:00 amRNSInterim Results
6th Sep 20177:00 amRNSAppointment of Joint Corporate Broker
1st Aug 20177:00 amRNSNotification of Interim Results
28th Jul 20174:21 pmRNSUpdate on Diclectin
25th Jul 20175:40 pmRNSChanges to interests of a significant shareholder
25th Jul 20175:34 pmRNSChanges to interests of a significant shareholder
18th Jul 20177:00 amRNSHalf Year Trading Update
3rd Jul 20172:29 pmRNSChanges to interests of a significant shareholder
26th Jun 20175:31 pmRNSChanges to interests of a significant shareholder
22nd Jun 20175:22 pmRNSChanges to interests of a significant shareholder
21st Jun 20172:53 pmRNSApplication for block admission
19th Jun 20173:16 pmRNSChanges to interests of a significant shareholder
19th Jun 20172:37 pmRNSApplication for admission
14th Jun 20174:54 pmRNSApplication for admission
25th May 20173:20 pmRNSChanges to interests of a significant shareholder
25th May 201711:00 amRNSResult of AGM
25th May 20177:15 amRNSHardman Res.: Transformed International Business
25th May 20177:00 amRNSAGM Statement
22nd May 201710:10 amRNSApplication for admission
9th May 20171:50 pmRNSCorrection: Application for admission
8th May 20172:30 pmRNSApplication for admission
5th May 20176:10 pmRNSApplication for admission
5th May 20177:00 amRNSChanges to interests of a significant shareholder
5th May 20177:00 amRNSChanges to interests of a significant shareholder
4th May 20171:30 pmRNSChanges to interests of a significant shareholder
28th Apr 201712:15 pmRNSAnnual Report and AGM Notice
28th Apr 20179:45 amRNSChanges to interests of a significant shareholder
24th Apr 201711:33 amRNSChanges to interests of a significant shareholder
5th Apr 20171:30 pmRNSNotification of Major Interest in Shares
31st Mar 20174:59 pmRNSApplication for admission
29th Mar 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
2nd Mar 20177:00 amRNSNotification of Preliminary Results
14th Feb 20175:31 pmRNSPDMR shareholding
14th Feb 20175:30 pmRNSApplication for admission
7th Feb 20179:05 amRNSChanges to interests of a significant shareholder
31st Jan 20177:00 amRNSExercise of Share Options
25th Jan 20177:15 amRNSHardman Research: Potential of Diclectin
23rd Jan 20177:00 amRNSPre-Close Trading Update
16th Dec 20164:00 pmRNSExercise of Share Options
15th Dec 20164:50 pmRNSExercise of Share Options
12th Dec 20169:19 amRNSExercise of Share Options
9th Dec 201611:45 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20167:00 amRNSCapital Markets Event
30th Nov 20164:00 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.